Maria Chiara Tisi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Chiara Tisi has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Busca
Stem Cell Transplant Center, AOU Città Della Salute e Della Scienza di Torino, Turin, Italy
1 shared publication - Alice Di Rocco
Hematology, Department of Translational and Precision Medicine, University Sapienza, Rome, Italy
1 shared publication - Andrés José Maria Ferreri
Strategic Program on Lymphomas IRCCS San Raffaele Scientific Institute, Milano and Vita‐Salute San Raffaele University Milan Italy
1 shared publication - Angela Maria Quinto
UO Ematologia e Terapia Cellulare, IRCCS - Istituto Tumori "Giovanni Paolo II" Bari, Italy
1 shared publication - Angelica Spolzino
Dipartimento di Medicina e Chirurgia, Università degli Studi di Parma, 43125 Parma, Italy
1 shared publication - Anna Candoni
Department of Medical and Surgical Sciences, Section of Hematology University of Modena and Reggio Emilia, Azienda Ospedaliero‐Universitaria di Modena Modena Italy
1 shared publication
Latest Publications
- Open Access
Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
Background: Rituximab plus bendamustine (BR), and rituximab, bendamustine, and cytarabine (R-BAC) are well-known induction therapies in elderly patients with mantle cell lymphoma (MCL), according to clinical guidelines. However, a direct comparison between the two regimens has never been performed. Methods: In this multicentre retrospective study, we compared the outcome of patients with newly diagnosed MCL, treated with BR or R-BAC. Primary endpoint was 2-year progression-free survival (PFS). Inclusion bias was assessed using a propensity score stratified by gender, age, MCL morphology, and MIPI score. Results: After adjusting by propensity score, we identified 156 patients (53 BR, 103 R-BAC) with median age of 72 (53–90). Median follow-up was 46 months (range 12–133). R-BAC was administered in a 2-day schedule or with attenuated dose in 51% of patients. Patients treated with R-BAC achieved CR in 91% of cases, as compared with 60% for BR (p < 0.0001). The 2-year PFS was 87 ± 3% and 64 ± 7% for R-BAC and BR, respectively (p = 0.001). In terms of toxicity, R-BAC was associated with significantly more pronounced grade 3–4 thrombocytopenia than BR (50% vs. 17%). Conclusions: This study indicates that R-BAC, even when administered with judiciously attenuated doses, is associated with significantly prolonged 2-year PFS than BR in elderly patients with previously untreated MCL.
Open AccessRituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
Background: Rituximab plus bendamustine (BR), and rituximab, bendamustine, and cytarabine (R-BAC) are well-known induction therapies in elderly patients with mantle cell lymphoma (MCL), according to clinical guidelines. However, a direct comparison between the two regimens has never been performed. Methods: In this multicentre retrospective study, we compared the outcome of patients with newly diagnosed MCL, treated with BR or R-BAC. Primary endpoint was 2-year progression-free survival (PFS). Inclusion bias was assessed using a propensity score stratified by gender, age, MCL morphology, and MIPI score. Results: After adjusting by propensity score, we identified 156 patients (53 BR, 103 R-BAC) with median age of 72 (53–90). Median follow-up was 46 months (range 12–133). R-BAC was administered in a 2-day schedule or with attenuated dose in 51% of patients. Patients treated with R-BAC achieved CR in 91% of cases, as compared with 60% for BR (p < 0.0001). The 2-year PFS was 87 ± 3% and 64 ± 7% for R-BAC and BR, respectively (p = 0.001). In terms of toxicity, R-BAC was associated with significantly more pronounced grade 3–4 thrombocytopenia than BR (50% vs. 17%). Conclusions: This study indicates that R-BAC, even when administered with judiciously attenuated doses, is associated with significantly prolonged 2-year PFS than BR in elderly patients with previously untreated MCL.
- Open Access
- 5 November 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)
Central nervous system (CNS) involvement is a rare but almost fatal complication of diffuse large B-cell lymphoma (DLBCL). There is no consensus on the optimal CNS risk model and prophylaxis treatment. We conducted in all FIL centers a web-based survey, focused on algorithms used in routine practice to identify DLBCL patients at high CNS risk involvement. We collect the centers’ characteristics and the disease incidence, the CNS risk assessment and the diagnostic method and finally the type of prophylaxis used. Sixty-three out of 110 centers fulfilled the survey. 46% treat >30 DLBCL/years (yrs) and 40% 11-30 cases/yrs. In the last 5 yrs, 6% of centers reported >10 DLBCL with CNS and systemic localization at the diagnosis, 30% reported 4-10 cases and 48% reported 4 in 21% of centers, whereas in 56% of centers this procedure was performed in patients with either CNS-IPI >4 or with high-risk extranodal site. Patients with double\triple hit lymphoma, with double/triple + ABC and double expresser lymphomas were considered at high CNS risk in 44%, 49% and 49% of centers, respectively. CNS disease status was assessed by CSF evaluation and imaging in 79% and 73% of centers, respectively. CNS prophylaxis consisted of intrathecal Methotrxate (MTX) in 58% of centers and in HD-MTX (1.5 to 3 gr/sqm) in 40% of centers. This survey shows real-life practice and the differences in diagnosis and prophylaxis of CNS in DLBCL patients.
- 5 November 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessCNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)
Central nervous system (CNS) involvement is a rare but almost fatal complication of diffuse large B-cell lymphoma (DLBCL). There is no consensus on the optimal CNS risk model and prophylaxis treatment. We conducted in all FIL centers a web-based survey, focused on algorithms used in routine practice to identify DLBCL patients at high CNS risk involvement. We collect the centers’ characteristics and the disease incidence, the CNS risk assessment and the diagnostic method and finally the type of prophylaxis used. Sixty-three out of 110 centers fulfilled the survey. 46% treat >30 DLBCL/years (yrs) and 40% 11-30 cases/yrs. In the last 5 yrs, 6% of centers reported >10 DLBCL with CNS and systemic localization at the diagnosis, 30% reported 4-10 cases and 48% reported 4 in 21% of centers, whereas in 56% of centers this procedure was performed in patients with either CNS-IPI >4 or with high-risk extranodal site. Patients with double\triple hit lymphoma, with double/triple + ABC and double expresser lymphomas were considered at high CNS risk in 44%, 49% and 49% of centers, respectively. CNS disease status was assessed by CSF evaluation and imaging in 79% and 73% of centers, respectively. CNS prophylaxis consisted of intrathecal Methotrxate (MTX) in 58% of centers and in HD-MTX (1.5 to 3 gr/sqm) in 40% of centers. This survey shows real-life practice and the differences in diagnosis and prophylaxis of CNS in DLBCL patients.
- 1 February 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 158, 103203
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper
- 1 February 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 158, 103203
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper